Article Text
Review
Ablative therapy for liver tumours
Abstract
Established ablative therapies for the treatment of primary and secondary liver tumours, including percutaneous ethanol injection, cryotherapy, and radiofrequency ablation, are discussed. Newer techniques such as magnetic resonance imaging guided laser interstitial thermal therapy of liver tumours has produced a median survival rate of 40.8 months after treatment. The merits of this newly emerging technique are discussed, together with future developments, such as focused ultrasound therapy, which holds the promise of non-invasive thermoablation treatment on an outpatient basis.
- ablative therapy
- hepatocellular carcinoma
- hepatic metastases
- magnetic resonance imaging
- RFA, radiofrequency ablation
- PEI, percutaneous ethanol injection
- LITT, laser interstitial thermal therapy
- HCC, hepatocellular carcinoma
- CRC, colorectal carcinoma
- HBV, hepatitis B virus
- HCV, hepatitis C virus
- US, ultrasound
- CT, computed tomography
- MRI, magnetic resonance imaging
- FUS, focused ultrasound
- Nd:YAG, neodymium yttrium aluminium garnet
Statistics from Altmetric.com
- RFA, radiofrequency ablation
- PEI, percutaneous ethanol injection
- LITT, laser interstitial thermal therapy
- HCC, hepatocellular carcinoma
- CRC, colorectal carcinoma
- HBV, hepatitis B virus
- HCV, hepatitis C virus
- US, ultrasound
- CT, computed tomography
- MRI, magnetic resonance imaging
- FUS, focused ultrasound
- Nd:YAG, neodymium yttrium aluminium garnet